Rune Andreas Kroken
Overview
Explore the profile of Rune Andreas Kroken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stromme M, Thue Augustsson M, Bartz-Johannessen C, Stautland A, Mykletun A, Kroken R, et al.
Psychol Med
. 2024 Dec;
:1-9.
PMID: 39651581
Background: The lifetime prevalence of suicide is around 5% in patients with schizophrenia. Non-adherence to antipsychotic medication is an important risk factor, but prospective studies investigating joint effects of antipsychotic...
2.
Rossum I, Slot M, van Hell H, Bossong M, Berger G, Aschauer H, et al.
Schizophr Bull
. 2024 Oct;
PMID: 39450759
Background And Hypotheses: In the past 2 decades, substantial effort has been put into research on therapeutic options for people at ultra-high risk (UHR) for developing a first episode of...
3.
Drosos P, Johnsen E, Bartz-Johannessen C, Larsen T, Reitan S, Rettenbacher M, et al.
Schizophr Res
. 2024 Jul;
271:9-18.
PMID: 39002529
Schizophrenia is a serious mental disorder, and monitoring remission is a widely used measure of effectiveness of the treatment provided. It is very important to identify possible factors correlating with...
4.
Varden Gjerde K, Bartz-Johannessen C, Steen V, Andreassen O, Steen N, Ueland T, et al.
Schizophr Res
. 2024 Apr;
267:223-229.
PMID: 38574562
Background: Endothelial inflammation may be involved in the pathogenesis of schizophrenia, and cellular adhesion molecules (CAMs) on endothelial cells may facilitate leukocyte binding and transendothelial migration of cells and inflammatory...
5.
Stromme M, Bartz-Johannessen C, Kjelby E, Mehlum L, Mykletun A, Kroken R, et al.
Acta Psychiatr Scand
. 2024 Jan;
149(3):244-255.
PMID: 38225748
Introduction: Associations between psychiatric disorders and mortality have been extensively studied, but limited evidence exists regarding influence of clinical characteristics on mortality risk, at the time of acute psychiatric hospitalization....
6.
Kjelby E, Gjestad R, Fathian F, Sinkeviciute I, Alisauskiene R, Anda L, et al.
J Clin Psychopharmacol
. 2023 Dec;
44(1):76-78.
PMID: 38100787
No abstract available.
7.
Kjelby E, Gjestad R, Fathian F, Sinkeviciute I, Alisauskiene R, Anda L, et al.
J Clin Psychopharmacol
. 2023 Apr;
43(3):246-258.
PMID: 37083542
Background: Depressive symptoms are frequent in schizophrenia and associated with a poorer outcome. Currently, the optimal treatment for depressive symptoms in schizophrenia remains undetermined. Amisulpride, aripiprazole, and olanzapine all have...
8.
Marquardt L, Craven A, Hugdahl K, Johnsen E, Kroken R, Kusztrits I, et al.
Brain Sci
. 2022 Oct;
12(10).
PMID: 36291316
Background: Transcranial direct current stimulation (tDCS) is used as treatment for auditory verbal hallucinations (AVH). The theory behind the treatment is that tDCS activity in prefrontal cognitive control areas, which...
9.
Stromme M, Bartz-Johannesen C, Kroken R, Mehlum L, Johnsen E
Schizophr Res
. 2022 Aug;
248:35-41.
PMID: 35933742
Background: Evidence is limited for the associations between use of psychotropic medications and overactive, aggressive, disruptive or agitated behavior (OADA) in clinical practice. Aims: To investigate the associations between risk...
10.
Drosos P, Johnsen E, Bartz-Johannessen C, Larsen T, Reitan S, Rettenbacher M, et al.
World J Psychiatry
. 2022 Apr;
12(3):521-532.
PMID: 35433321
Background: Antipsychotic drugs remain the mainstay of schizophrenia treatment; however, their effectiveness has been questioned, and it is not possible to predict the response to a specific antipsychotic drug in...